![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
ElevateBio
Main (gene editing) focus: Novel gene- and cell therapies
Company stage: Clinical
Diseases: Undisclosed
Genome editing tool: CRISPR-Cas, base editing, CRISPRa/CRISPRi
Funding stage: Private
Location: Cambridge, MA, USA
Website: https://www.elevate.bio/
Pipeline: https://www.elevate.bio/portfolio-pipeline
Partnerships: Life Edit Therapeutics (acquired)
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Elevatebio_logo_b74eb76fbd_6a1c62aaf9.jpg)
ElevateBio is a gene- and cell therapy company. It is engaged in the genome-editing field through its acquisition of Life Edit Therapeutics that develops novel CRISPR-Cas, base editing and CRISPRa/CRISPRi systems. The company anticipates to integrate these novel gene-editing technologies with its existing iPSC, viral vector, and cell engineering platforms.